Wyeth, formerly one of the companies owned by American Home Products Corporation (AHP), was a pharmaceutical company. The company was based in Madison, New Jersey, USA. They were known for manufacturing the over-the-counter (OTC) drugs Robitussin and the analgesic Advil (ibuprofen), as well as the prescription drugs Premarin and Effexor, which both boast over US$3 billion in sales annually.
Campaign Finance$28,010 Given
- contributions under $200 are not reported, and so are not included in totals.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
RegulationsMentioned in 127 dockets; Submitted to 3 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Wyeth" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Wyeth
- Toggle 2 FDA Patent Term Extension Application for Prevnar 13®, U.S. Patent No.5,614,382 2011
- Toggle 1 FDA Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications - CLOSED 2011
- Toggle 1 LMSO Labor-Management Reporting and Disclosure Act; Interpretation of the "Advice" Exemption 2011
Mentions in Document Text
View all mentions data for Wyeth
- Toggle 20 EPA Greenhouse Gas New Source Performance Standard for Electric Generating Units 2011
- Toggle 13 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Healthcare Professional Survey of Prescription Drug Promotion 2012
- Toggle 13 CMS Certain Preventive Services Under the Affordable Care Act 2012
- Toggle 5 FSIS Poultry Slaughter Inspection 2011
- Toggle 4 BOEM Request for comments on the Proposed 2012-2017 Oil and Gas Leasing Program 2011
- Toggle 4 EPA Emergency Petition Seeking Suspension of Registration for Clothianidin 2012
- Toggle 4 EPA 2,4-D Choline Salt. Proposed Use on AAD-12 Soybeans Containing DAS 68416-4 2012
- Toggle 4 BLM Notice of Proposed Rule: Oil and Gas; Well Stimulation, Including Hydraulic Fracturing, on Federal and Indian Lands 43 CFR 3160 2012
- Toggle 3 FDA Patent Term Extension Application for NUEDEXTA™, U.S. Patent No. 5,206,248 2011
- Toggle 3 FDA Patent Term Extension Application for Prevnar 13®, U.S. Patent No.5,614,382 2011
Federal Spending2 contracts
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Wyeth||2011||Centers For Disease Control||TAS::75 0512::TAS 00HCVGBC-2010-82344 - PFIZER/WYETH PEDIATRIC VACCINE CONTRACT||$308,849,720|
|Wyeth||2011||Centers For Disease Control||00HCVGBC-2010-82344 - PFIZER/WYETH PEDIATRIC VACCINE CONTRACT||$213,282,692|
Contractor Misconduct1 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Health||None||Daniel v. Wyeth (Prempro)||2011||Judgment Against Defendant||$1,681,650|
Advisory Committees3 people on 3 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.